Patterson panies(US:PDCO)2023-08-29 16:00Financial Performance - Net sales for the three months ended July 29, 2023, were $1,576,745, an increase of 3.5% compared to $1,523,265 for the same period in 2022[10] - Gross profit for the same period was $319,055, representing a gross margin of approximately 20.2%, compared to $312,133 in the prior year[10] - Operating income increased to $38,222, up 9.4% from $34,844 in the previous year[10] - Net income attributable to Patterson Companies, Inc. was $31,234, a 27.1% increase from $24,590 in the same quarter last year[10] - Earnings per share (EPS) for the quarter were $0.33 (basic) and $0.32 (diluted), compared to $0.25 for both in the prior year[10] - Comprehensive income for the quarter was $38,759, compared to $19,530 in the same quarter last year, showing a significant increase of 97.5%[10] - Net income for the three months ended July 29, 2023, was $31,130,000, an increase of 28.5% compared to $24,260,000 for the same period in 2022[17] Assets and Liabilities - Total assets as of July 29, 2023, were $2,883,631, a slight increase from $2,879,146 as of April 29, 2023[8] - Total liabilities increased to $1,772,390 from $1,760,611 in the previous quarter[8] - Stockholders' equity decreased to $1,111,241 from $1,118,535 in the prior quarter[8] - Cash and cash equivalents decreased to $108,573 from $159,669 in the previous quarter[8] - The total assets measured at fair value as of July 29, 2023, amounted to $354,046, compared to $407,787 as of April 29, 2023, reflecting a decrease of 13.2%[65] Cash Flow and Investments - Net cash used in operating activities decreased to $(253,366,000) from $(302,539,000), reflecting improved cash flow management[17] - The company reported net cash provided by investing activities of $223,818,000, slightly down from $238,355,000 in the prior year[17] - The company paid $1,108,000 related to the acquisition of Miller Vet Holdings, LLC, as part of its strategy to expand its veterinary services[34] - Total purchase price for recent acquisitions, including holdbacks, was $37,535,000, enhancing the company's offerings in the veterinary sector[36] Customer Financing and Receivables - Customer financing contracts sold amounted to $83,873 in Q1 fiscal 2024, compared to $73,612 in Q1 fiscal 2023, reflecting a year-over-year increase of 15.3%[50] - The company recorded a loss of $8,927 related to these contracts sold in Q1 fiscal 2024, compared to a gain of $988 in Q1 fiscal 2023[50] - Cash collections on financed receivables sold were $66,678 in Q1 fiscal 2024, down from $84,094 in Q1 fiscal 2023, indicating a decrease of 20.7%[50] - The ending balance of the deferred purchase price (DPP) receivable was $210,260,000, up from $192,275,000 year-over-year[42] - The ending DPP receivable balance as of July 29, 2023, was $105,609, up from $102,979 as of April 29, 2023, showing an increase of 2.5%[52] Segment Performance - Animal Health segment net sales reached $1,010,990 for the three months ended July 29, 2023, up from $960,370 in the prior year[79] - Dental segment operating income was $38,670 for the three months ended July 29, 2023, compared to $36,895 in the same period of 2022[79] - Corporate segment net sales were $(1,545) for the three months ended July 29, 2023, compared to $4,978 in the same period last year[79] Tax and Compliance - The effective income tax rate increased to 23.3% for the three months ended July 29, 2023, up from 21.9% for the same period in 2022[73] - The company maintained compliance with minimum current ratio and maximum leverage ratio covenants as of July 29, 2023[52] Derivative Instruments and Fair Value - The fair value of derivative instruments as of July 29, 2023, was $34,565, an increase from $29,085 as of April 29, 2023[61] - The estimated fair value of the company's debt was $481,296 as of July 29, 2023, compared to a carrying value of $486,603[71] Other Financial Metrics - The company declared dividends of $0.26 per common share, consistent with the previous year[10] - The company recorded losses of $3,424,000 related to receivables during the three months ended July 29, 2023, compared to $1,435,000 in the same period last year[40] - Bad debt write-offs since the internal financing program began in 1994 have amounted to less than 1% of the loans originated[52] - The carrying value of the investment in Vetsource was $56,849 as of July 29, 2023, with a put option valued at $25,757[70]